[Reaction of autogenous cortisol production in patients with extensive psoriasis vulgaris or atopic dermatitis following external administration of a 0.25% prednicarbate salve (W/O emulsion)].
Prednicarbate is a new potent corticoid without halogenic groups which has been developed for topical application. During one week's application of 0.25% prednicarbate ointment (W/O Emulsion) two times daily in an ordinary dose, there could not be proved any significant suppression of the basal production of plasma cortisol in patients suffering from extensive dermatoses (such as psoriasis vulgaris or atopic dermatitis). After the end of treatment, investigation on the reservoir within the adrenal cortex by means of ACTH short test showed sufficient stimulation capacity of the adrenal gland in all patients examined.
D000287:Administration, Topical; D000293:Adolescent; D000324:Adrenocorticotropic Hormone; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000324:Adrenocorticotropic Hormone; D011239:Prednisolone; C035287:prednicarbate; D006854:Hydrocortisone
Reaktion der körpereigenen Cortisol-Produktion bei Patienten mit ausgedehnter Psoriasis vulgaris oder atopischer Dermatitis nach externer Applikation einer 0.25%igen Prednicarbat-Salbe (W/O-Emulsion).